» Articles » PMID: 24971005

Synthesis, Characterization, and Evaluation of Poly (D,L-lactide-co-glycolide)-based Nanoformulation of MiRNA-150: Potential Implications for Pancreatic Cancer Therapy

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2014 Jun 28
PMID 24971005
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs are small (18-22 nucleotide long) noncoding RNAs that play important roles in biological processes through posttranscriptional regulation of gene expression. Their aberrant expression and functional significance are reported in several human malignancies, including pancreatic cancer. Recently, we identified miR-150 as a novel tumor suppressor microRNA in pancreatic cancer. Furthermore, expression of miR-150 was downregulated in the majority of tumor cases, suggesting that its restoration could serve as an effective approach for pancreatic cancer therapy. In the present study, we developed a nanoparticle-based miR-150 delivery system and tested its therapeutic efficacy in vitro. Using double emulsion solvent evaporation method, we developed a poly (D,L-lactide-co-glycolide) (PLGA)-based nanoformulation of miR-150 (miR-150-NF). Polyethyleneimine (a cationic polymer) was incorporated in PLGA matrix to increase the encapsulation of miR-150. Physical characterization of miR-150-NF demonstrated that these nanoparticles had high encapsulation efficiency (~78%) and exhibited sustained release profile. Treatment of pancreatic cancer cells with miR-150-NF led to efficient intracellular delivery of miR-150 mimics and caused significant downregulation of its target gene (MUC4) expression. Inhibition of MUC4 correlated with a concomitant decrease in the expression of its interacting partner, HER2, and repression of its downstream signaling. Furthermore, treatment of pancreatic cancer cells with miR-150-NF suppressed their growth, clonogenicity, motility, and invasion. Together, these findings suggest that PLGA-based nanoformulation could potentially serve as a safe and effective nanovector platform for miR-150 delivery to pancreatic tumor cells.

Citing Articles

Circ_0011446 Regulates Intramuscular Adipocyte Differentiation in Goats via the miR-27a-5p/FAM49B Axis.

Wang J, Lv J, Liu K, Li Y, Zhu J, Xiong Y Int J Mol Sci. 2025; 26(5).

PMID: 40076914 PMC: 11900246. DOI: 10.3390/ijms26052294.


Novel insight and perspectives of nanoparticle-mediated gene delivery and immune-modulating therapies for pancreatic cancer.

Wang X, Yin X, Li Y, Zhang S, Hu M, Wei M J Nanobiotechnology. 2024; 22(1):771.

PMID: 39696302 PMC: 11656556. DOI: 10.1186/s12951-024-02975-7.


Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer.

Le M, Nguyen H, Nguyen X, Do X, Mai B, Ngoc Nguyen H Heliyon. 2023; 9(11):e22080.

PMID: 38058618 PMC: 10696070. DOI: 10.1016/j.heliyon.2023.e22080.


Optimization and characterization of miRNA-129-5p-encapsulated poly (lactic--glycolic acid) nanoparticles to reprogram activated microglia.

Kalashnikova I, Cambell H, Kolpek D, Park J Nanoscale Adv. 2023; 5(13):3439-3452.

PMID: 37383067 PMC: 10295030. DOI: 10.1039/d3na00149k.


Nano-drug delivery system for pancreatic cancer: A visualization and bibliometric analysis.

Zhao J, Zou F, Zhu J, Huang C, Bu F, Zhu Z Front Pharmacol. 2022; 13:1025618.

PMID: 36330100 PMC: 9622975. DOI: 10.3389/fphar.2022.1025618.


References
1.
Soofiyani S, Baradaran B, Lotfipour F, Kazemi T, Mohammadnejad L . Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv Pharm Bull. 2013; 3(2):249-55. PMC: 3848228. DOI: 10.5681/apb.2013.041. View

2.
Patil Y, Panyam J . Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm. 2008; 367(1-2):195-203. PMC: 2660441. DOI: 10.1016/j.ijpharm.2008.09.039. View

3.
Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F . Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine. 2011; 6:877-95. PMC: 3124394. DOI: 10.2147/IJN.S18905. View

4.
Wang J, Lu Z, Wientjes M, Au J . Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010; 12(4):492-503. PMC: 2977003. DOI: 10.1208/s12248-010-9210-4. View

5.
Singh S, Srivastava S, Bhardwaj A, Owen L, Singh A . CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer. 2010; 103(11):1671-9. PMC: 2994230. DOI: 10.1038/sj.bjc.6605968. View